The Canadian province of British Columbia said on Monday that its public drug plan will switch as many as 20,400 patients from three branded biologic drugs to cheap near-copies called biosimilars, saving an estimated C$96.6 million ($71.9 million)over three years.
British Columbia to be first Canadian province to switch patients to biosimilars
More from Pharma NewsMore posts in Pharma News »
- Brazil coronavirus deaths climb to 46,510, cases near 1 million
- Requiring masks ‘political hazard’ as COVID-19 surges in California breadbasket
- Mothers as ‘trauma surgeons:’ the anguish of raising black boys in America
- Record spike in new coronavirus cases reported in six U.S. states as reopening accelerates